[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transmission-vertical\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transmission-vertical":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,59,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":38,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100592937","enhanced-mentor-mother-strategy-for-pregnant-and-postpartum-women-living-with-hiv-100592937",false,"NCT06999928","Enhanced Mentor Mother Strategy for Pregnant and Postpartum Women Living With HIV","Pilot Implementation-Effectiveness Study of an Enhanced Mentor Mother Strategy","PIE-eMMs","Inclusion Criteria:\n\n* Pregnant and postpartum women living with HIV (and their infants born during the study)\n* ≥18 years of age\n* Enrolled in PMTCT services at BFSDH\n* Able to understand and provide informed consent in English or Kiswahili\n\nExclusion Criteria:\n\n* Women who are not pregnant or postpartum\n* \\\u003C18 years of age\n* Not enrolled in PMTCT services at BFSDH\n* Unable to understand and provide informed consent in English or Kiswahili\n* Cognitive impairment that would interfere with ability to participate in the study",true,"FEMALE","18 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","Mentor Mothers (MMs) are peer supporters who help pregnant and postpartum women living with HIV (WLHIV) as they receive prevention of mother-to-child transmission of HIV (PMTCT) services in resource-limited settings like Kenya. Differentiated service delivery (DSD) is a care model that tailors services based on clients' needs, helping to improve both the quality and efficiency of care.\n\nThis hybrid implementation-effectiveness study will test whether an enhanced MM strategy that uses DSD can be successfully carried out and improve health outcomes for mothers and infants. The study will take place at Burnt Forest Sub-District Hospital (BFSDH) in Kenya.\n\nResearchers will ask:\n\n* Can the enhanced MM strategy be delivered as planned and accepted by patients and staff?\n* Does the strategy improve clinical outcomes like keeping mothers in PMTCT care, achieving HIV viral suppression, completing infant HIV testing, and preventing HIV transmission to infants? Researchers will compare health outcomes before and after the strategy is introduced at BFSDH, and also compare outcomes at other similar clinics that continue with standard MM services.\n\nWomen who choose to participate will meet with a MM during their routine antenatal and postnatal clinic visits. They will be offered the enhanced MM support, but can choose to receive standard care if they prefer.",[28,29,30,31,32,33,34,35,36,37],"Hiv","Transmission Vertical","Viremia","Adherence, Treatment","Stigmatization","Socioeconomic Adversity","Health Care Utilization","Health Care Acceptability","Peer Group","Mothers",[39,40,41,42,43,44,45],"prevention of mother-to-child transmission","retention","implementation","mentor mothers","differentiated service delivery","maternal-child health","Kenya","RECRUITING","2025-07-14",{"date":49,"type":50},"2025-07-15","ACTUAL",{"date":52,"type":50},"2025-07-10",{"date":54,"type":22},"2026-10-12",{"name":56,"class":57},"Indiana University","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":17,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":72,"conditions":73,"keywords":79,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100595727","transmission-of-oncogenic-hpv-infection-among-families-100595727","NCT07036211","Transmission of Oncogenic HPV Infection Among Families","TREVINO","Inclusion Criteria:\n\n* Patient with colposcopy clinic detected persisting HR-HPV infection\n* Patient with diagnosed cervical cancer\n* Patient with diagnosed OSCC\n* Patients' sexual partners of women or men that are referred to the colposcopy\u002Fgynecological oncology\u002FENT\n* offspring (over 12 years old) of the referred couples\n\nExclusion Criteria:\n\n* Candidate who don't speak Finnish","ALL","12 Years","100 Years",{"count":70,"type":22},700,"OBSERVATIONAL","The goal of the Transmission of Oncogenic HPV Infection Among Families (TREVINO) study is to improve understanding of how high-risk human papillomavirus (HPV) infections are transmitted within families. The research focuses on transmission between sexual partners and between parents and children. It also examines how the various microbes may influence the persistence of HPV infections and the development of HPV-related cancers.\n\nThe study will include up to 300 couples recruited from gynecology and ear, nose, and throat (ENT) clinics in Finland, as well as their children. Participants include individuals with persistent HPV infection, cervical precancer or cancer, or HPV-related head and neck cancer, along with their partners and potentially their offspring.\n\nParticipants will provide self-collected samples from the oral and genital areas at multiple time points over up to five years. Questionnaires addressing medical, behavioural, and environmental factors will be completed.\n\nThe study is conducted at Tampere University Hospital and Kuopio University Hospital in Finland. Results will inform HPV screening and prevention programs, improve understanding of family-level transmission, and identify potential microbial and genetic markers linked to cancer risk.",[74,75,76,29,77,78],"Human Papilloma Virus (HPV)","Cervical Carcinoma","Oropharyngeal Carcinoma","Transmission","Human Papillomavirus Infection",[80,81,82],"Oropharyngeal cancer","Cervical cancer","HPV","NOT_YET_RECRUITING","2025-06-16",{"date":86,"type":50},"2025-06-25",{"date":88,"type":22},"2025-08",{"date":90,"type":22},"2031-12",{"name":92,"class":57},"Tampere University Hospital",2,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":17,"sex":66,"minAge":19,"maxAge":4,"enrollmentInfo":102,"targetDuration":104,"studyType":71,"phases":4,"briefSummary":105,"conditions":106,"keywords":111,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":93},"100535188","find-hdv-and-determine-its-status-in-turkey-100535188","NCT06248580","Find HDV and Determine Its Status in Turkey","Find HDV and Determine Its Status in Turkey \"SITU(HD)VATION\"","SITUHDVATION","Inclusion Criteria:\n\n* Adults (Age≥18)\n* Being HBsAg positive for at least six months\n* Being a citizen of the Republic of Türkiye\n\nExclusion Criteria:\n\n* There are no exclusion criteria in this study.",{"count":103,"type":22},20000,"13 Months","The aim of these study to determine the prevalence of hepatitis Delta virus (HDV) infections and the prognosis of HDV patients in Turkey's southeast. The investigators intend to arrange training sessions for 250 family physicians in Diyarbakir, Batman, Mardin, and Sanliurfa in order to determine those goals. The investigators will talk about diagnosing hepatitis B virus (HBV), HDV, hepatitis C virus (HCV), and Human Immunodeficiency virus (HIV) infections during these events. To ensure that patients with simultaneous HDV infection are evaluated for HIV\u002FHCV and to detect liver fibrosis with a non-invasive method.",[107,108,109,110,29],"Chronic Hepatitis D Infection","Fibrosis, Liver","Hepatocellular Carcinoma","Cirrhosis, Liver",[112,109,113],"Chronic hepatitis D","Liver Cirrhosis","2024-08-08",{"date":116,"type":50},"2024-08-12",{"date":118,"type":50},"2024-03-11",{"date":120,"type":22},"2025-03-01",{"name":122,"class":57},"Yaşar Bayındır, MD"]